The first GOST for bioprinting in medicine has been approved in Russia

Rosstandart has approved the country's first national standard in the field of bioprinting (GOST R 72595-2026), which regulates the creation of tissue and organ equivalents. This was reported on the agency's website on April 20.

"The new standard establishes terms and definitions used in science, technology and manufacturing, and also establishes the basic principles of technology, which forms the basis for the systemic development of one of the most promising areas of modern biomedicine," the report says.

According to the standard, three-dimensional bioprinting is defined as an additive technology for creating biological objects from natural materials, including cells, to restore body functions.

GOST also establishes clear requirements for the composition of bio ink and the technical characteristics of bioprinters. The ministry explained that the introduction of uniform rules will allow the industry to move from disparate experiments to a full-fledged market.

"The adoption of GOST creates conditions for the formation of transparent mechanisms for the commercialization of research and development, the transition from disparate laboratory solutions to industrial implementation and mass production of biomedical products," the press service emphasizes.

It is noted that the document lays the foundation for the formation of a new industry, providing uniform operating rules for existing market participants and future technology companies.

Life with movement: sensitive prostheses to be launched in Russia

Due to this, people who have lost limbs will be able to recognize the size and rigidity of objects.

On April 17, Boris Lopatukhin, CEO of Legaltek, an expert in the field of information technology, spoke about the role of AI in drug development. According to the expert, pharmaceutical companies face a high proportion of failures at all stages of development — from the search for a molecule to clinical trials.